Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer

doi:10.3390/cells10081890

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/34383

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34383

Title:	Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer
Authors:	Lai, Yi-Wen Hsu, Wen-Jing Lee, Wen-Ying Chen, Cheng-Hsun Tsai, Ying-Huei Dai, Jia-Zih Yang, Ching-Chieh Lin, Cheng-Wei
Contributors:	Taipei Med Univ, Coll Med, Sch Med, Dept Biochem & Mol Cell Biol Taipei Med Univ, Coll Med, Grad Inst Med Sci Chi Mei Med Ctr, Dept Cytopathol Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Pharm Taipei Med Univ, Wan Fang Hosp, Cell Physiol & Mol Image Res Ctr Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr
Keywords:	EMT glycolysis YBX1 triple-negative breast cancer
Date:	2021
Issue Date:	2023-11-11 11:48:34 (UTC+8)
Publisher:	MDPI
Abstract:	Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as it shows a high capacity for metastasis and poor prognoses. Metabolic reprogramming is one of the hallmarks of cancer, and aberrant glycolysis was reported to be upregulated in TNBC. Thus, identifying metabolic biomarkers for diagnoses and investigating cross-talk between glycolysis and invasiveness could potentially enable the development of therapeutics for patients with TNBC. In order to determine novel and reliable metabolic biomarkers for predicting clinical outcomes of TNBC, we analyzed transcriptome levels of glycolysis-related genes in various subtypes of breast cancer from public databases and identified a distinct glycolysis gene signature, which included ENO1, SLC2A6, LDHA, PFKP, PGAM1, and GPI, that was elevated and associated with poorer prognoses of TNBC patients. Notably, we found a transcription factor named Y-box-binding protein 1 (YBX1) to be strongly associated with this glycolysis gene signature, and it was overexpressed in TNBC. A mechanistic study further validated that YBX1 was upregulated in TNBC cell lines, and knockdown of YBX1 suppressed expression of those glycolytic genes. Moreover, YBX1 expression was positively associated with epithelial-to-mesenchymal transition (EMT) genes in breast cancer patients, and suppression of YBX1 downregulated expressions of EMT-related genes and tumor migration and invasion in MDA-MB-231 and BT549 TNBC cells. Our data revealed an YBX1-glycolysis-EMT network as an attractive diagnostic marker and metabolic target in TNBC patients.
Relation:	CELLS-BASEL, v.10, n.8
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
cells10081890.pdf		37236Kb	Adobe PDF	98	View/Open
index.html		0Kb	HTML	225	View/Open

Loading...